IM Cannabis

Company Overview

Snapshot

Founded in January 2008, IM Cannabis operates with 11–50 employees. The company has raised $68.25 million across 15 funding rounds and has been public on NASDAQ since March 2021. In March 2026, IM Cannabis announced a strategic entry into the cyber drone interception and satellite intelligence markets by signing a non-binding agreement to acquire a 51% stake in Blackaxe Technologies.

Business overview

IM Cannabis is an international medical cannabis company focused on providing premium cannabis products to patients in key markets such as Israel and Germany. The company leverages a data-driven approach and a global supply chain to operate within the Health Tech & Life Sciences sector, specifically targeting the Pharma & Medical Biotechnology and Medical Cannabis categories.

Strategic signal

In June 2026, IM Cannabis announced its intention to sell its European activities, expecting to significantly reduce debt by CAD$10.5 million. This strategic move signals a significant operational realignment for the company, indicating a potential shift in its core market focus and a drive towards financial restructuring to improve its balance sheet.

Company Intelligence Q&A

When did IM Cannabis go public on NASDAQ?

IM Cannabis became public on NASDAQ in March 2021.

What strategic acquisition did IM Cannabis announce in March 2026?

In March 2026, IM Cannabis announced a non-binding agreement to acquire a 51% stake in Blackaxe Technologies, marking a strategic entry into the cyber drone interception and satellite intelligence markets.

What were IM Cannabis's financial results for the first quarter of 2026?

IM Cannabis Corp. announced its first quarter 2026 financial results in May 2026.

What significant operational change did IM Cannabis announce in June 2026?

In June 2026, IM Cannabis Corp. announced its entry into a Letter of Intent to sell its European activities, with an expectation to significantly reduce debt by CAD$10.5 million.